Holen Sie sich die Stockscreener-App
55.86
0.07%
-0.04
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$55.90
Offen:
$55.72
24-Stunden-Volumen:
9.36M
Relative Volume:
0.62
Marktkapitalisierung:
$113.72B
Einnahmen:
$48.03B
Nettoeinkommen (Verlust:
$6.05B
KGV:
18.86
EPS:
2.9615
Netto-Cashflow:
$15.30B
1W Leistung:
+4.49%
1M Leistung:
+10.29%
6M Leistung:
+17.21%
1J Leistung:
-1.67%
1-Tages-Spanne:
$55.62
$56.33
1-Wochen-Bereich:
$52.06
$56.97
52-Wochen-Spanne:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
55.86 | 113.80B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,063.56 | 971.27B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
204.39 | 495.71B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
220.08 | 396.12B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.53 | 275.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.54 | 271.43B | 54.45B | 14.42B | 17.15B | 7.333 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Did UBS’s Pipeline-Driven Upgrade Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative? - Yahoo Finance UK
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? - TradingView — Track All Markets
Scotiabank raises Bristol-Myers Squibb stock price target to $60 on growth - Investing.com
Next Level Private LLC Has $2.54 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Scotiabank Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Sector Perform Rating - MarketScreener
Is Bristol Myers Squibb Company Celegne Contingent stock attractive post correctionMarket Performance Report & Consistent Growth Equity Picks - ulpravda.ru
Will Bristol Myers Squibb Company stock outperform foreign stocksJuly 2025 PostEarnings & Weekly High Return Stock Forecasts - ulpravda.ru
The Escalator: Argenx, Gilead Sciences, Bristol Myers Squibb and more - Medical Marketing and Media
BMS-partnered ADC shows first Phase III success in hard-to-treat cancer - The Pharma Letter
Is Bristol Myers Squibb (BMY) Quietly Recasting Its Post-Patent Story With Opdivo And KarXT Moves? - simplywall.st
Bristol-Myers' buy of Celgene gets endorsement from top Wall Street advisory firms - The Pharma Letter
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves - Yahoo Finance UK
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
3 Drug Stocks to Buy at a Discount - Finviz
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs - Benzinga
Bristol-Myers Squibb (BMY) Upgraded to Buy with Raised Price Tar - GuruFocus
Bristol-Myers Squibb stock upgraded to Buy at UBS on promising 2026 catalysts - Investing.com India
BMY Stock Quote Price and Forecast - CNN
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again - Finviz
Bristol-Myers Squibb Earns ENERGY STAR® Partner of the Year Award for Third Consecutive Year - CSRwire
Bristol Myers Squibb Company $BMY Position Decreased by D.A. Davidson & CO. - MarketBeat
Areas of interest - Bristol-Myers Squibb Company
Is Bristol Myers Squibb a buy, sell, or hold in 2026? - MSN
Myocardial Infarction Market Is Booming Worldwide 2025-2032 | - openPR.com
Bristol-Myers Squibb (BMY) Stock Analysis: Navigating Potential Upside In Healthcare Giants - DirectorsTalk Interviews
The Motley Fool: Dividends and a chance for growth - Dallas News
Bristol Myers Squibb: Deep-Value Pharma Play Or Value Trap As Wall Street Turns Cautious? - AD HOC NEWS
Biological Therapies for Cancer Global Markets Report 2025-2030: Merck, BMS, Roche, AstraZeneca, Joh - PharmiWeb.com
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? - Benzinga
Biological Therapies for Cancer Global Markets Report 2025-2030: Merck, BMS, Roche, AstraZeneca, Johnson & Johnson, and Novartis Drive Growth Through Pipeline Expansion and Strategic CollaborationsResearchAndMarkets.com - FinancialContent
How to watch Bristol Myers Squibb at a major healthcare conference live - Stock Titan
Bristol Myers Squibb Just Shocked Wall Street: Is BMY the Most Slept-On Stock Right Now? - AD HOC NEWS
List of 25 Acquisitions by Bristol-Myers Squibb (Jan 2026) - Tracxn
Looking Into Bristol-Myers Squibb Co's Recent Short InterestBristol-Myers Squibb (NYSE:BMY) - Benzinga
Ex-Dividend Reminder: Encompass Health, Bristol Myers Squibb and Federal Realty Investment Trust - Nasdaq
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now? - Yahoo Finance
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY - ts2.tech
Goldman Sachs Raises Bristol-Myers (BMY) Target, Keeps Neutral Rating - Finviz
BMY vs AMGN: Which Biotech Stock Is More Resilient Now? - Finviz
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026? - The Motley Fool
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever - Finviz
Bristol-Myers Squibb Stock Finds a Floor as Wall Street Bets on a Late-Cycle Rebound - AD HOC NEWS
Diversified Trust Co Has $4.56 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Inside Bristol-Myers Squibb: How a Quiet Pharma Giant Is Re?Architecting the Future of Cancer and Im - AD HOC NEWS
What does Wall Street think about Bristol-Myers Squibb Company (BMY)? - MSN
What Does Wall Street Think About Bristol-Myers Squibb Company (BMY)? - Finviz
10 Best Affordable Healthcare Stocks to Buy Now - Insider Monkey
Bristol-Myers Squibb Stock: Defensive Pharma Giant Tests Investor Patience As Wall Street Turns Sele - AD HOC NEWS
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears - ts2.tech
Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open - ts2.tech
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.87%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):